Glucose measurement of intensive care unit patient plasma samples using a fixed-wavelength mid-infrared spectroscopy system

James Krinsley, Kelly Bochicchio, Christopher Calentine, Grant Bochicchio

Research output: Contribution to journalArticle

Abstract

Objective: Glycemic control is a rapidly developing field in intensive care medicine with the aim of reducing mortality, morbidity, and cost. Current intensive care unit (ICU) glucose measurement technologies are susceptible to interference from medications, volume expanders, and other substances present in critically ill patients. We hypothesized that a fixed-wavelength mid-infrared (mid-IR) spectroscopy system would be accurate for measuring glucose levels of ICU patients. Research Design and Methods: This is a prospective investigation of plasma samples from two diferent institutions treating a heterogeneous population of ICU patients. The first 292 samples were collected from 86 patients admitted to Stamford Hospital, and the next 352 samples were collected from 75 patients from three ICUs at the University of Maryland. Plasma samples were measured on a Fourier-transform infrared or a proprietary spectrometer, with a glucose prediction algorithm to correct for spectral interference, which were compared with reference measurements taken using a YSI 2300 glucose analyzer. Results: Glucose values ranged from 24 to 343 mg/dl. Numerous medications and injury/disease states were observed in the patient populations, with metoprolol, fentanyl, and multiple organ failure the most prevalent. Despite these interferents, there was a high correlation (r ≥ 0.94) and low standard error (≤12.8 mg/dl) between the predicted glucose values and those of the YSI 2300 STAT Plus reference instrument in the three studies. A total of 95.1% of the 644 values in the three studies met International Organization for Standardization 15197 criteria. Conclusion: These results suggest that a fixed-wavelength mid-IR spectrometer can measure glucose accurately in the plasma of ICU patients.

Original languageEnglish (US)
Pages (from-to)294-301
Number of pages8
JournalJournal of diabetes science and technology
Volume6
Issue number2
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Intensive care units
Intensive Care Units
Glucose
Infrared spectroscopy
Spectrum Analysis
Plasmas
Wavelength
Infrared spectrometers
Metoprolol
Multiple Organ Failure
Fentanyl
Fourier Analysis
Critical Care
Critical Illness
Standardization
Population
Medicine
Spectrometers
Fourier transforms
Research Design

Keywords

  • Continuous glucose monitoring
  • Intensive care unit
  • Interference
  • Spectroscopy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Bioengineering
  • Biomedical Engineering

Cite this

Glucose measurement of intensive care unit patient plasma samples using a fixed-wavelength mid-infrared spectroscopy system. / Krinsley, James; Bochicchio, Kelly; Calentine, Christopher; Bochicchio, Grant.

In: Journal of diabetes science and technology, Vol. 6, No. 2, 2012, p. 294-301.

Research output: Contribution to journalArticle

Krinsley, James ; Bochicchio, Kelly ; Calentine, Christopher ; Bochicchio, Grant. / Glucose measurement of intensive care unit patient plasma samples using a fixed-wavelength mid-infrared spectroscopy system. In: Journal of diabetes science and technology. 2012 ; Vol. 6, No. 2. pp. 294-301.
@article{a8b11613e858417b8f8f83e02176240c,
title = "Glucose measurement of intensive care unit patient plasma samples using a fixed-wavelength mid-infrared spectroscopy system",
abstract = "Objective: Glycemic control is a rapidly developing field in intensive care medicine with the aim of reducing mortality, morbidity, and cost. Current intensive care unit (ICU) glucose measurement technologies are susceptible to interference from medications, volume expanders, and other substances present in critically ill patients. We hypothesized that a fixed-wavelength mid-infrared (mid-IR) spectroscopy system would be accurate for measuring glucose levels of ICU patients. Research Design and Methods: This is a prospective investigation of plasma samples from two diferent institutions treating a heterogeneous population of ICU patients. The first 292 samples were collected from 86 patients admitted to Stamford Hospital, and the next 352 samples were collected from 75 patients from three ICUs at the University of Maryland. Plasma samples were measured on a Fourier-transform infrared or a proprietary spectrometer, with a glucose prediction algorithm to correct for spectral interference, which were compared with reference measurements taken using a YSI 2300 glucose analyzer. Results: Glucose values ranged from 24 to 343 mg/dl. Numerous medications and injury/disease states were observed in the patient populations, with metoprolol, fentanyl, and multiple organ failure the most prevalent. Despite these interferents, there was a high correlation (r ≥ 0.94) and low standard error (≤12.8 mg/dl) between the predicted glucose values and those of the YSI 2300 STAT Plus reference instrument in the three studies. A total of 95.1{\%} of the 644 values in the three studies met International Organization for Standardization 15197 criteria. Conclusion: These results suggest that a fixed-wavelength mid-IR spectrometer can measure glucose accurately in the plasma of ICU patients.",
keywords = "Continuous glucose monitoring, Intensive care unit, Interference, Spectroscopy",
author = "James Krinsley and Kelly Bochicchio and Christopher Calentine and Grant Bochicchio",
year = "2012",
doi = "10.1177/193229681200600212",
language = "English (US)",
volume = "6",
pages = "294--301",
journal = "Journal of diabetes science and technology",
issn = "1932-2968",
publisher = "Diabetes Technology Society",
number = "2",

}

TY - JOUR

T1 - Glucose measurement of intensive care unit patient plasma samples using a fixed-wavelength mid-infrared spectroscopy system

AU - Krinsley, James

AU - Bochicchio, Kelly

AU - Calentine, Christopher

AU - Bochicchio, Grant

PY - 2012

Y1 - 2012

N2 - Objective: Glycemic control is a rapidly developing field in intensive care medicine with the aim of reducing mortality, morbidity, and cost. Current intensive care unit (ICU) glucose measurement technologies are susceptible to interference from medications, volume expanders, and other substances present in critically ill patients. We hypothesized that a fixed-wavelength mid-infrared (mid-IR) spectroscopy system would be accurate for measuring glucose levels of ICU patients. Research Design and Methods: This is a prospective investigation of plasma samples from two diferent institutions treating a heterogeneous population of ICU patients. The first 292 samples were collected from 86 patients admitted to Stamford Hospital, and the next 352 samples were collected from 75 patients from three ICUs at the University of Maryland. Plasma samples were measured on a Fourier-transform infrared or a proprietary spectrometer, with a glucose prediction algorithm to correct for spectral interference, which were compared with reference measurements taken using a YSI 2300 glucose analyzer. Results: Glucose values ranged from 24 to 343 mg/dl. Numerous medications and injury/disease states were observed in the patient populations, with metoprolol, fentanyl, and multiple organ failure the most prevalent. Despite these interferents, there was a high correlation (r ≥ 0.94) and low standard error (≤12.8 mg/dl) between the predicted glucose values and those of the YSI 2300 STAT Plus reference instrument in the three studies. A total of 95.1% of the 644 values in the three studies met International Organization for Standardization 15197 criteria. Conclusion: These results suggest that a fixed-wavelength mid-IR spectrometer can measure glucose accurately in the plasma of ICU patients.

AB - Objective: Glycemic control is a rapidly developing field in intensive care medicine with the aim of reducing mortality, morbidity, and cost. Current intensive care unit (ICU) glucose measurement technologies are susceptible to interference from medications, volume expanders, and other substances present in critically ill patients. We hypothesized that a fixed-wavelength mid-infrared (mid-IR) spectroscopy system would be accurate for measuring glucose levels of ICU patients. Research Design and Methods: This is a prospective investigation of plasma samples from two diferent institutions treating a heterogeneous population of ICU patients. The first 292 samples were collected from 86 patients admitted to Stamford Hospital, and the next 352 samples were collected from 75 patients from three ICUs at the University of Maryland. Plasma samples were measured on a Fourier-transform infrared or a proprietary spectrometer, with a glucose prediction algorithm to correct for spectral interference, which were compared with reference measurements taken using a YSI 2300 glucose analyzer. Results: Glucose values ranged from 24 to 343 mg/dl. Numerous medications and injury/disease states were observed in the patient populations, with metoprolol, fentanyl, and multiple organ failure the most prevalent. Despite these interferents, there was a high correlation (r ≥ 0.94) and low standard error (≤12.8 mg/dl) between the predicted glucose values and those of the YSI 2300 STAT Plus reference instrument in the three studies. A total of 95.1% of the 644 values in the three studies met International Organization for Standardization 15197 criteria. Conclusion: These results suggest that a fixed-wavelength mid-IR spectrometer can measure glucose accurately in the plasma of ICU patients.

KW - Continuous glucose monitoring

KW - Intensive care unit

KW - Interference

KW - Spectroscopy

UR - http://www.scopus.com/inward/record.url?scp=84865121695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865121695&partnerID=8YFLogxK

U2 - 10.1177/193229681200600212

DO - 10.1177/193229681200600212

M3 - Article

C2 - 22538138

AN - SCOPUS:84865121695

VL - 6

SP - 294

EP - 301

JO - Journal of diabetes science and technology

JF - Journal of diabetes science and technology

SN - 1932-2968

IS - 2

ER -